Cost- effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery

Biochemia Medica

Volumn 25, Issue 2, 2015, Pages 262-271

  Petrovic, Stanislava ^a   Bogavac Stanojevic, Natasa ^a   Lakic, Dragana ^a   Peco Antic, Amira ^b,c   Vulicevic, Irena ^c   Ivanisevic, Ivana ^c   Kotur Stevuljevic, Jelena ^a   Jelic Ivanovic, Zorana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

Author keywords

Acute kidney injury; Biomarkers; Cardiac surgery; Children; Cost effectiveness analysis

Indexed keywords

CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CYSTATIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE COST; HEART SURGERY; MORTALITY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ACUTE KIDNEY INJURY; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; COST; ECONOMIC MODEL; ECONOMICS; FEMALE; HEART DEFECTS, CONGENITAL; HUMAN; INFANT; MALE; POSTOPERATIVE COMPLICATIONS; PRESCHOOL CHILD; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADOLESCENT; BIOMARKERS; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; CYSTATINS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; LIPOCALINS; MALE; MODELS, ECONOMIC; POSTOPERATIVE COMPLICATIONS; PROTO-ONCOGENE PROTEINS;

EID: 84930421453     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2015.027     Document Type: Article

References (33)

1. Blinder JJ, Goldstein SL, Lee VV, Baycroft A, Fraser CD, Nelson D, et al. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg 2012;143:368-74. http://dx.doi.org/10.1016/j. jtcvs.2011.06.021.
2. Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen- Philbrook H, Coca SG, et al. TRIBE-AKI Consortium: incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med 2011;39:1493-9. http://dx.doi.org/10.1097/ CCM.0b013e31821201d3.
3. Morgan CJ, Zappitelli M, Robertson CM, Alton GY, Sauve RS, Joffe AR, et al. Western Canadian Complex Pediatric Therapies Follow-Up Group. Risk factors for and outcomes of acute kidney injury in neonates undergoing complex cardiac surgery. J Pediatr 2011;162:120-7. http://dx.doi. org/10.1016/j.jpeds.2012.06.054.
4. Ricci Z, Netto R, Garisto C, Iacoella C, Favia I, Cogo P. Whole- blood assessment of neutrophil gelatinase-associated lipocalin versus pRIFLE for acute kidney injury diagnosis and prognosis after pediatric cardiac surgery: cross-sectional study. Pediatr Crit Care Med 2012;13:667-70. http://dx.doi. org/10.1097/PCC.0b013e3182601167.
5. Shaw NJ, Brocklebank JT, Dickinson DF, Wilson N, Walker DR. Long-term outcome for children with acute renal failure following cardiac surgery. Int J Cardio 1991;31:161-5. http://dx.doi.org/10.1016/0167-5273(91)90211-7.
6. Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006;69:184-9. http:// dx.doi.org/10.1038/sj.ki.5000032.
7. Mammen C, Al Abbas A, Skippen P, Nadel H, Levine D, Collet JP, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012;59:523-30. http://dx.doi.org/10.1053/j.ajkd.2011.10.048.
8. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012;27:363-73. http://dx.doi.org/10.1007/s00467-011- 1939-1.
9. Kramer A, Stel VS, Tizard J, Verrina E, Ronnholm K, Palsson R, et al. Characteristics and survival of young adults who started renal replacement therapy during childhood. Nephrol Dial Transplant 2009;24:926-33. http://dx.doi. org/10.1093/ndt/gfn542.
10. Smidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase- associated lipocalin. J Am Soc Nephrol 2007;18:407-13. http://dx.doi.org/10.1681/ASN.2006080882.
11. Yokoyama T, Kamijo IA, Sugaya T, Hoshino S, Yasuda T, Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009;174:2096-106. http://dx.doi. org/10.2353/ajpath.2009.080780.
12. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute kidney failure by serum Cystatin C. Kidney Int 2004;66:1115-22. http://dx.doi.org/10.1111/j.1523-1755.2004.00861.x.
13. Peco-Antic A, Ivanisevic I, Vulicevic I, Kotur-Stevuljevic J, Ilic S, Ivanisevic J, et al. Biomarkers of acute kidney injury in pediatric cardiac surgery. Clin Biochem 2013;46:1244-51. http://dx.doi.org/10.1016/j.clinbiochem.2013.07.008.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
15. Phillips C, Thompson G. What is a QALY? New market, United Kingdom: Hayward Medical Communications; 2003. Available at: www.evidence-based-medicine.co.uk. Accessed May 15, 2014.
16. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571-90.
17. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007;71:1028-35. http://dx.doi.org/10.1038/sj.ki.5002231.
18. U.S. renal data system, USRDS. Annual data report: Atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005.
19. Samuel SM, Tonelli MA, Foster BJ, Alexander RT, Nettel-Aguirre A, Soo A, et al. Survival in pediatric dialysis and transplant patients. Clin J Am Soc Nephrol 2011;6:1094-9. http://dx.doi.org/10.2215/CJN.04920610.
20. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62_07. pdf. Accessed June 7, 2014.
21. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press, 2006.
22. Cost-Effectiveness Analysis (CEA) registry. The Center for the Evaluation of Value and Risk in Health. The Institute for Clinical Research and Health Policy Studies. Tufts Medical Center. Available at: www.research.tufts-nemc.org. Accessed June 7, 2014.
23. Shaw AD, Chalfin DB, Kleintjens J. The Economic Impact and Cost-Effectiveness of Urinary Neutrophil Gelatinase-Associated Lipocalin After Cardiac Surgery. Clin Ther 2011;33:1713-25. http://dx.doi.org/10.1016/j.clinthera.2011.09.014.
24. Ricci Z, Luciano R, Favia I, Garisto C, Muraca M, Morelli S, et al. High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care 2011;15:R160. http://dx.doi.org/10.1186/cc10295.
25. Price list, St. John Hopkins hospital. Available at: http://pathology. jhu.edu/department/services/ResearchPricing.cfm. Accessed April 24, 2015.
26. R&D systems. Available at: www.rndsystems.com. Accessed April 24, 2014.
27. Healthcare Cost and Utilization Project (HCUP). Kids' Inpatient Database (KID). Agency for Healthcare Research and Quality, Rockville, MD. 2009. Available at: www.hcup-us. ahrq.gov/kidoverview.jsp. Accessed April 16, 2014.
28. Hoerger TJ, Wittenborn JS, Seqel JE, Burrows NR, Imai K, Eqqers P, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010;55:463-4. http://dx.doi.org/10.1053/j. ajkd.2009.11.017.
29. U.S. Renal Data System, USRDS. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.
30. Yen EF, Hardinger K, Brennan DC, Woodward RS, Desai NM, Crippin JS, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004;4:1703-8. http:// dx.doi.org/10.1111/j.1600-6143.2004.00565.x.
31. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-78. http://dx.doi. org/10.1586/14737167.8.2.165.
32. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93. http://dx.doi.org/10.1126/science. 3287615.
33. Parikh CR. A point-of-care device for acute kidney injury: a fantastic, futuristic, or frivolous "measure"? Kidney Int 2009;76:8-10. http://dx.doi.org/10.1038/ki.2009.125.